Here’s what you should know:
1. Xifaxan currently accounts for about 50 percent of all IBS-D prescriptions.
2. Although Bausch’s immense debt limits its purchasing power, Mr. Solorio argued Bausch should take the risk and partner with Synergy Pharmaceuticals for access to Trulance, its drug for treating irritable bowel syndrome with constipation.
3. Bausch’s GI segment, Salix Pharmaceuticals, remains a growth driver for the company. While Bausch’s Ortho Dermatologics segment shrunk in the third quarter, Salix posted 3 percent organic growth.
4. For Bausch to continue growingorganically, the company needs to partner with Synergy to acquire 50 percent of the rights to Trulance, the columnist said. He said, “[Bausch] would own the two most important assets on IBS, and Trulance could achieve blockbuster status along Xifaxan.”
More articles on coding, billing and collections:
Da Vinci Xi grape surgery becomes internet phenomenon — 4 highlights
Here’s what CMS pays for 10 gastroenterology procedures
Baptist Clay Medical Center prepares to open surgery center — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.